![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhNJHkfrYE1OJ5HRcBj6Nb2SoMfvu8s2rUsi8tOOhq3KictDr5mxDPUwnxMEVYtnZF4Q510u-at1giin3qyBapmjjQXHqvXQyjG5C8y1aSgypGa3P7A7Wwhr1m2e3H3TOm17lIxI4mp1IiJ/s320/GLMD2021060320210615-764739.png)
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of a once-daily, oral therapy for the treatment of liver diseases. It is developing Aramchol, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
http://www.priceseries.com/trade/GLMD-Galmed-Pharmaceuticals-Ltd-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2021060320210615.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments